Structured Review

U73122 PLC ikk inhibitors
<t>IKK</t> inhibition reduced growth of V2D1 tumors (A) Blood from wt or DBA1- Rag1 −/− -mice was analyzed for CD3 and B220. (B) V2D1-cells (1 × 10 6 ) were injected subcutaneously into the flanks of DBA/1- Rag1 −/− -mice and tumor area was assessed for 6 weeks using a Mitutoyo Quick Mini caliper. Growing tumors were either treated with DMSO/PBS (blue line) or with IKK-inhibitor <t>VII</t> (red line) (25 μM). [Data represent the mean SD of 10 mice with tumors ( p
Ikk Inhibitors, supplied by U73122 PLC, used in various techniques. Bioz Stars score: 89/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ikk inhibitors/product/U73122 PLC
Average 89 stars, based on 9 article reviews
Price from $9.99 to $1999.99
ikk inhibitors - by Bioz Stars, 2020-11
89/100 stars

Images

1) Product Images from "Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cells"

Article Title: Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cells

Journal: Oncotarget

doi:

IKK inhibition reduced growth of V2D1 tumors (A) Blood from wt or DBA1- Rag1 −/− -mice was analyzed for CD3 and B220. (B) V2D1-cells (1 × 10 6 ) were injected subcutaneously into the flanks of DBA/1- Rag1 −/− -mice and tumor area was assessed for 6 weeks using a Mitutoyo Quick Mini caliper. Growing tumors were either treated with DMSO/PBS (blue line) or with IKK-inhibitor VII (red line) (25 μM). [Data represent the mean SD of 10 mice with tumors ( p
Figure Legend Snippet: IKK inhibition reduced growth of V2D1 tumors (A) Blood from wt or DBA1- Rag1 −/− -mice was analyzed for CD3 and B220. (B) V2D1-cells (1 × 10 6 ) were injected subcutaneously into the flanks of DBA/1- Rag1 −/− -mice and tumor area was assessed for 6 weeks using a Mitutoyo Quick Mini caliper. Growing tumors were either treated with DMSO/PBS (blue line) or with IKK-inhibitor VII (red line) (25 μM). [Data represent the mean SD of 10 mice with tumors ( p

Techniques Used: Inhibition, Mouse Assay, Injection

The IL-3-induced IKK2 activation mediates mitogenic signaling (A, B) BMMCs were pre-incubated with the IKK-inhibitor VII and were stimulated with IL-3. Lysates were analyzed by westernblotting (A) or cells were probed with [H 3 ]thymidine and analyzed by β -counting (B) ( p
Figure Legend Snippet: The IL-3-induced IKK2 activation mediates mitogenic signaling (A, B) BMMCs were pre-incubated with the IKK-inhibitor VII and were stimulated with IL-3. Lysates were analyzed by westernblotting (A) or cells were probed with [H 3 ]thymidine and analyzed by β -counting (B) ( p

Techniques Used: Activation Assay, Incubation

Survival of V2D1 cells depends on the IKK-mediated IL-3 production (A) V2D1 cells were cultured in IL-3-free medium for different time periods. Lysates were analyzed by westernblotting. (B–D) V2D1 cells were treated with the IKK-inhibitor VII. Lysates were analyzed by westernblotting (B) or cells were probed with [H 3 ]thymidine (C) or PI (D) . Cells were analyzed by β -counting (C) or by flow cytometry (D) ( C ; p
Figure Legend Snippet: Survival of V2D1 cells depends on the IKK-mediated IL-3 production (A) V2D1 cells were cultured in IL-3-free medium for different time periods. Lysates were analyzed by westernblotting. (B–D) V2D1 cells were treated with the IKK-inhibitor VII. Lysates were analyzed by westernblotting (B) or cells were probed with [H 3 ]thymidine (C) or PI (D) . Cells were analyzed by β -counting (C) or by flow cytometry (D) ( C ; p

Techniques Used: Cell Culture, Flow Cytometry, Cytometry

The IL3-induced IKK activation does not mediate IκBα degradation (A, B) BMMCs were stimulated with IL-3 (A, B) or IL-33 (B) Lysates were analyzed by westernblotting. (C) BMMCs were stimulated with IL-3 or IL-33. Supernatants were collected and analyzed for IL-6. (D–F) NFκB-EGFP-MC/9 cells were pre-incubated with the IKK-inhibitor VII and stimulated with IL-3 or IL-33. Lysates were analyzed by westernblotting (D) or cells were analyzed for EGFP-production by flow cytometry (E) or collected supernatants were analyzed for IL-6 (F)
Figure Legend Snippet: The IL3-induced IKK activation does not mediate IκBα degradation (A, B) BMMCs were stimulated with IL-3 (A, B) or IL-33 (B) Lysates were analyzed by westernblotting. (C) BMMCs were stimulated with IL-3 or IL-33. Supernatants were collected and analyzed for IL-6. (D–F) NFκB-EGFP-MC/9 cells were pre-incubated with the IKK-inhibitor VII and stimulated with IL-3 or IL-33. Lysates were analyzed by westernblotting (D) or cells were analyzed for EGFP-production by flow cytometry (E) or collected supernatants were analyzed for IL-6 (F)

Techniques Used: Activation Assay, Incubation, Flow Cytometry, Cytometry

Related Articles

Lysis:

Article Title: Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cells
Article Snippet: .. Stimulation and lysis BMMCs (106 cells/ml) were IL-3-starved (1 h), pre-incubated (30 min) with SP600125 (JNK-inhibitor), SU6656 (SFK-inhibitor), IKK-inhibitors (VII, PS-1145, BMS-34554) and U73122 (PLC inhibitor) (If not other stated all these inhibitors were used in a concentration of 5 μM). .. Furthermore we used the protein biosynthesis inhibitor cyclohexamide (340 μM), the PLD1 inhibitor CAY10594 (10 μM), and the Ca2+ chelator BAPTA-AM (10 μM) or ionomycin (in a concentration from 0,5–10 ng/ml) (all inhibitors were from Merck Millipore).

Concentration Assay:

Article Title: Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cells
Article Snippet: .. Stimulation and lysis BMMCs (106 cells/ml) were IL-3-starved (1 h), pre-incubated (30 min) with SP600125 (JNK-inhibitor), SU6656 (SFK-inhibitor), IKK-inhibitors (VII, PS-1145, BMS-34554) and U73122 (PLC inhibitor) (If not other stated all these inhibitors were used in a concentration of 5 μM). .. Furthermore we used the protein biosynthesis inhibitor cyclohexamide (340 μM), the PLD1 inhibitor CAY10594 (10 μM), and the Ca2+ chelator BAPTA-AM (10 μM) or ionomycin (in a concentration from 0,5–10 ng/ml) (all inhibitors were from Merck Millipore).

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 89
    U73122 PLC ikk inhibitors
    <t>IKK</t> inhibition reduced growth of V2D1 tumors (A) Blood from wt or DBA1- Rag1 −/− -mice was analyzed for CD3 and B220. (B) V2D1-cells (1 × 10 6 ) were injected subcutaneously into the flanks of DBA/1- Rag1 −/− -mice and tumor area was assessed for 6 weeks using a Mitutoyo Quick Mini caliper. Growing tumors were either treated with DMSO/PBS (blue line) or with IKK-inhibitor <t>VII</t> (red line) (25 μM). [Data represent the mean SD of 10 mice with tumors ( p
    Ikk Inhibitors, supplied by U73122 PLC, used in various techniques. Bioz Stars score: 89/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ikk inhibitors/product/U73122 PLC
    Average 89 stars, based on 9 article reviews
    Price from $9.99 to $1999.99
    ikk inhibitors - by Bioz Stars, 2020-11
    89/100 stars
      Buy from Supplier

    Image Search Results


    IKK inhibition reduced growth of V2D1 tumors (A) Blood from wt or DBA1- Rag1 −/− -mice was analyzed for CD3 and B220. (B) V2D1-cells (1 × 10 6 ) were injected subcutaneously into the flanks of DBA/1- Rag1 −/− -mice and tumor area was assessed for 6 weeks using a Mitutoyo Quick Mini caliper. Growing tumors were either treated with DMSO/PBS (blue line) or with IKK-inhibitor VII (red line) (25 μM). [Data represent the mean SD of 10 mice with tumors ( p

    Journal: Oncotarget

    Article Title: Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cells

    doi:

    Figure Lengend Snippet: IKK inhibition reduced growth of V2D1 tumors (A) Blood from wt or DBA1- Rag1 −/− -mice was analyzed for CD3 and B220. (B) V2D1-cells (1 × 10 6 ) were injected subcutaneously into the flanks of DBA/1- Rag1 −/− -mice and tumor area was assessed for 6 weeks using a Mitutoyo Quick Mini caliper. Growing tumors were either treated with DMSO/PBS (blue line) or with IKK-inhibitor VII (red line) (25 μM). [Data represent the mean SD of 10 mice with tumors ( p

    Article Snippet: Stimulation and lysis BMMCs (106 cells/ml) were IL-3-starved (1 h), pre-incubated (30 min) with SP600125 (JNK-inhibitor), SU6656 (SFK-inhibitor), IKK-inhibitors (VII, PS-1145, BMS-34554) and U73122 (PLC inhibitor) (If not other stated all these inhibitors were used in a concentration of 5 μM).

    Techniques: Inhibition, Mouse Assay, Injection

    The IL-3-induced IKK2 activation mediates mitogenic signaling (A, B) BMMCs were pre-incubated with the IKK-inhibitor VII and were stimulated with IL-3. Lysates were analyzed by westernblotting (A) or cells were probed with [H 3 ]thymidine and analyzed by β -counting (B) ( p

    Journal: Oncotarget

    Article Title: Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cells

    doi:

    Figure Lengend Snippet: The IL-3-induced IKK2 activation mediates mitogenic signaling (A, B) BMMCs were pre-incubated with the IKK-inhibitor VII and were stimulated with IL-3. Lysates were analyzed by westernblotting (A) or cells were probed with [H 3 ]thymidine and analyzed by β -counting (B) ( p

    Article Snippet: Stimulation and lysis BMMCs (106 cells/ml) were IL-3-starved (1 h), pre-incubated (30 min) with SP600125 (JNK-inhibitor), SU6656 (SFK-inhibitor), IKK-inhibitors (VII, PS-1145, BMS-34554) and U73122 (PLC inhibitor) (If not other stated all these inhibitors were used in a concentration of 5 μM).

    Techniques: Activation Assay, Incubation

    Survival of V2D1 cells depends on the IKK-mediated IL-3 production (A) V2D1 cells were cultured in IL-3-free medium for different time periods. Lysates were analyzed by westernblotting. (B–D) V2D1 cells were treated with the IKK-inhibitor VII. Lysates were analyzed by westernblotting (B) or cells were probed with [H 3 ]thymidine (C) or PI (D) . Cells were analyzed by β -counting (C) or by flow cytometry (D) ( C ; p

    Journal: Oncotarget

    Article Title: Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cells

    doi:

    Figure Lengend Snippet: Survival of V2D1 cells depends on the IKK-mediated IL-3 production (A) V2D1 cells were cultured in IL-3-free medium for different time periods. Lysates were analyzed by westernblotting. (B–D) V2D1 cells were treated with the IKK-inhibitor VII. Lysates were analyzed by westernblotting (B) or cells were probed with [H 3 ]thymidine (C) or PI (D) . Cells were analyzed by β -counting (C) or by flow cytometry (D) ( C ; p

    Article Snippet: Stimulation and lysis BMMCs (106 cells/ml) were IL-3-starved (1 h), pre-incubated (30 min) with SP600125 (JNK-inhibitor), SU6656 (SFK-inhibitor), IKK-inhibitors (VII, PS-1145, BMS-34554) and U73122 (PLC inhibitor) (If not other stated all these inhibitors were used in a concentration of 5 μM).

    Techniques: Cell Culture, Flow Cytometry, Cytometry

    The IL3-induced IKK activation does not mediate IκBα degradation (A, B) BMMCs were stimulated with IL-3 (A, B) or IL-33 (B) Lysates were analyzed by westernblotting. (C) BMMCs were stimulated with IL-3 or IL-33. Supernatants were collected and analyzed for IL-6. (D–F) NFκB-EGFP-MC/9 cells were pre-incubated with the IKK-inhibitor VII and stimulated with IL-3 or IL-33. Lysates were analyzed by westernblotting (D) or cells were analyzed for EGFP-production by flow cytometry (E) or collected supernatants were analyzed for IL-6 (F)

    Journal: Oncotarget

    Article Title: Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cells

    doi:

    Figure Lengend Snippet: The IL3-induced IKK activation does not mediate IκBα degradation (A, B) BMMCs were stimulated with IL-3 (A, B) or IL-33 (B) Lysates were analyzed by westernblotting. (C) BMMCs were stimulated with IL-3 or IL-33. Supernatants were collected and analyzed for IL-6. (D–F) NFκB-EGFP-MC/9 cells were pre-incubated with the IKK-inhibitor VII and stimulated with IL-3 or IL-33. Lysates were analyzed by westernblotting (D) or cells were analyzed for EGFP-production by flow cytometry (E) or collected supernatants were analyzed for IL-6 (F)

    Article Snippet: Stimulation and lysis BMMCs (106 cells/ml) were IL-3-starved (1 h), pre-incubated (30 min) with SP600125 (JNK-inhibitor), SU6656 (SFK-inhibitor), IKK-inhibitors (VII, PS-1145, BMS-34554) and U73122 (PLC inhibitor) (If not other stated all these inhibitors were used in a concentration of 5 μM).

    Techniques: Activation Assay, Incubation, Flow Cytometry, Cytometry